|1.||Markman, Maurie: 12 articles (01/2014 - 11/2003)|
|2.||Orlowski, Robert Z: 11 articles (11/2015 - 04/2005)|
|3.||Scambia, Giovanni: 10 articles (07/2014 - 01/2006)|
|4.||Scambia, G: 10 articles (11/2011 - 10/2003)|
|5.||Pujade-Lauraine, Eric: 9 articles (11/2015 - 08/2006)|
|6.||Vergote, Ignace: 9 articles (11/2015 - 07/2010)|
|7.||Sehouli, Jalid: 9 articles (06/2014 - 01/2006)|
|8.||Gabizon, Alberto: 9 articles (01/2014 - 01/2003)|
|9.||Lorusso, D: 9 articles (05/2012 - 10/2003)|
|10.||Monk, Bradley J: 8 articles (10/2012 - 01/2005)|
|1.||Ovarian Neoplasms (Ovarian Cancer)
03/01/2005 - "Given the chronic course of ovarian cancer, the improved tolerability profile of pegylated liposomal doxorubicin 40 mg/m2 combined with a convenient once-monthly dosing schedule may translate into an improved quality of life for patients with ovarian cancer."
03/01/2005 - "Pegylated liposomal doxorubicin has demonstrated efficacy in the treatment of recurrent/resistant ovarian cancer in several clinical trials utilizing a dose of 50 mg/m2 every 4 weeks. "
01/01/2006 - "This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management."
06/01/2014 - "Pegylated liposomal doxorubicin in the management of ovarian cancer: a systematic review and metaanalysis of randomized trials."
01/01/2013 - "The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials."
|2.||Breast Neoplasms (Breast Cancer)
12/27/2011 - "Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified."
01/01/2013 - "Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer."
01/01/2003 - "Growing evidence supports the use of pegylated liposomal doxorubicin as first-line treatment for patients with metastatic breast cancer, owing to its antitumor activity in both anthracycline-naïve patients and in patients with previous anthracycline exposure."
09/01/2013 - "Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial."
06/01/2013 - "The aim of our study was to determine the efficacy and safety of a metronomic regimen based in non-pegylated liposomal doxorubicin (NPLD) in advanced breast cancer patients. "
12/01/2006 - "Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors."
08/01/2006 - "To determine the level of activity and potential for use in future combinations, a phase II trial of pegylated liposomal doxorubicin as second-line therapy in advanced and recurrent cervical cancer was performed. "
06/01/2015 - "Treatment of HER2(+) SK-BR-3 and BT-474 cancer cells with αPEG:αHER2 and the clinically used chemotherapeutic agent PEGylated liposomal doxorubicin for 3 hours enhanced the in vitro effectiveness of PEGylated liposomal doxorubicin by over two orders of magnitude. "
05/01/2015 - "Pegylated liposomal doxorubicin is an important antineoplastic agent with activity in a variety of solid tumors. "
06/01/2014 - "The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model."
|4.||Kaposi Sarcoma (Kaposi's Sarcoma)
02/01/1998 - "Pegylated liposomal doxorubicin is an effective treatment for HIV-related Kaposi's sarcoma with a higher response rate than the BV combination. "
01/01/2009 - "Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi's sarcoma."
01/01/2009 - "Among chemotherapeutic agents, pegylated liposomal doxorubicin has become the preferred one for patients with HIV-associated Kaposi's sarcoma in Western countries. "
08/01/2008 - "Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin."
06/01/2008 - "Activity and safety of pegylated liposomal doxorubicin as first-line therapy in the treatment of non-visceral classic Kaposi's sarcoma: a multicenter study."
01/01/2008 - "Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma."
05/01/2015 - "We present a rare case of multiple myeloma who immediately developed serious stomatitis and esophatitis associated with minor palmar-plantar erythrodysesthesia after a single course of pegylated liposomal doxorubicin. "
07/01/2004 - "To report a case of reversible ageusia in a patient with multiple myeloma receiving pegylated liposomal doxorubicin. "
03/01/2007 - "These findings compare favorably with results reported for bortezomib alone and support the possibility that the bortezomib/pegylated liposomal doxorubicin regimen may provide superior efficacy against relapsed/refractory multiple myeloma."
11/01/2015 - "Long-term outcomes and updated clinical efficacy and safety data were evaluated for newly-diagnosed multiple myeloma patients treated on a phase II study of bortezomib and pegylated liposomal doxorubicin (PegLD). "
|8.||trabectedin (ecteinascidin 743)
|1.||Drug Therapy (Chemotherapy)
|2.||Highly Active Antiretroviral Therapy (HAART)